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Abstract
Aims: Cerebrovascular accidents (CVA) are considered among the most serious adverse events after tran-
scatheter aortic valve implantation (TAVI). The objective of the present study was to evaluate the frequency 
and timing of CVA after TAVI and to investigate the impact on clinical outcomes within 30 days of the 
procedure.
Methods and results: Between August 2007 and October 2011, 389 high-risk elderly patients with symp-
tomatic severe aortic stenosis underwent TAVI via transfemoral, transapical or subclavian access. A total of 
14 patients (3.6%) experienced at least one CVA within 30 days of follow-up and most events (74%) occurred 
within the first day of the procedure. Patients with CVA had an increased risk of all-cause (42.3% vs. 5.1%, 
ORadjusted 11.7, 95% CI 3.4-40.3, p<0.001) and cardiovascular mortality (38.4% vs. 4.6%, ORadjusted 10.5, 95% 
CI 2.9-37.8, p<0.001) compared to patients without CVA at 30 days of follow-up. Repeated device implanta-
tion attempts (ORadjusted 8.3, CI 2.1-33.3, p<0.003), chronic pulmonary disease (ORadjusted 4.7, CI 1.3-16.8, 
p=0.02) and body mass index <25 kg/m2 (ORadjusted 0.8, CI 0.7-0.9, p<0.01) emerged as independent predic-
tors of periprocedural CVA.
Conclusions: Cerebrovascular accidents among patients undergoing TAVI occur predominantly during the 
periprocedural period, are associated with multiple implantation attempts of the bioprosthesis and signifi-
cantly impair prognosis.
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Introduction
Transcatheter aortic valve implantation (TAVI) has rapidly evolved 
into a valuable treatment option for selected patients with severe, 
symptomatic degenerative aortic stenosis. As compared with medi-
cal treatment, TAVI improves survival and reduces the need for 
hospitalisation among patients no longer deemed to be surgical can-
didates1. In addition, TAVI has been shown to be non-inferior in 
terms of survival compared with surgical aortic valve replacement 
(SAVR) among selected, high-risk patients2. The favourable clini-
cal outcome of TAVI in randomised trials is supplemented by effec-
tive alleviation of symptoms, improvements of health-related 
quality of life and presence of cost-effectiveness3,4.
Careful patient selection, growing operator experience and on-
going improvements of transcatheter heart valve devices and tech-
nique have led to a substantial reduction of periprocedural 
complications. Notwithstanding, cerebrovascular accidents (CVA) 
remain among the most feared adverse events from a patient per-
spective, as they may result in total or partial loss of independence 
in everyday life. In addition, CVAs have an important impact on 
morbidity and mortality depending on the size and location of 
infarcted cerebral tissue. In the randomised Placement of 
Transcatheter Aortic Valves (PARTNER A) trial, patients allocated 
to TAVI had a trend towards a higher risk of major stroke compared 
with SAVR at one year, raising the question whether the procedure 
itself, the implanted prostheses or the antithrombotic treatment may 
influence the risk of CVAs5. The purpose of the present study was 
to describe the frequency and timing of periprocedural CVAs 
among consecutive, high-risk patients undergoing TAVI and to 
investigate their impact on clinical outcomes.
Methods
STUDY DESIGN AND PATIENT POPULATION
Between August 2007 and October 2011, 389 high-risk elderly 
patients with symptomatic severe aortic stenosis of the native valve 
were included into a prospective single-centre registry (Bern TAVI 
registry). Patients underwent TAVI with the self-expandable 
Medtronic CoreValve (MCV; Medtronic, Minneapolis, MN, USA) 
or the balloon-expandable Edwards SAPIEN transcatheter heart 
valve (ES; Edwards Lifesciences, Irvine, CA, USA) using the trans-
femoral, the transapical and the subclavian access routes as previ-
ously described6. Device and access route selection was based on 
individual anatomical characteristics and technical specifications of 
the prostheses. Patients were assigned to undergo a TAVI procedure 
following consensual agreement by the local Heart Team consisting 
of invasive cardiologists and cardiac surgeons.
The TAVI procedure was primarily performed using percutane-
ous femoral access, balloon predilatation of the stenotic valve fol-
lowing implantation of the prosthesis under conscious sedation or 
general anaesthesia. After the procedure, patients were admitted to 
a coronary care unit and monitored during the following 48 hours 
for rhythm disturbances, neurological deficits, vascular access site 
complications and other adverse events. In case of a suspected 
cerebrovascular event, patients were assessed by a board-certified 
neurologist and underwent neuroimaging by use of contrast-
enhanced computed tomography or magnetic resonance tomogra-
phy. The type and sequence of different imaging modalities (CT 
scan or MRI) among patients with suspected stroke were deter-
mined by the neurologist.
All patients were treated with acetylsalicylic acid 100 mg per day 
indefinitely and clopidogrel 75 mg per day for six months. 
Clopidogrel loading (600 mg) was performed one day prior to the 
procedure in patients who were not on chronic thienopyridine ther-
apy. In case of indication for oral anticoagulation, warfarin was 
combined with either acetylsalicylic acid or clopidogrel alone.
The study complied with the declaration of Helsinki and the reg-
istry was approved by the local medical ethics committee. All 
patients provided written informed consent to participate in the reg-
istry and to undergo prospective follow-up. The authors are solely 
responsible for the design and the conduct of this study, the study 
analyses, the drafting and editing of the paper and gave approval for 
its final content.
DATA COLLECTION
Patients were categorised into two study groups: (I) patients suffering 
at least one CVA within 30 days of the procedure (CVA), and (II) 
patients without CVA during the first thirty days (No CVA). Adverse 
events were assessed in hospital, and regular clinical follow-up was 
performed at 30 days and 12 months by means of a clinical in-hospi-
tal visit or a standardised telephone interview. All suspected adverse 
events were adjudicated by an unblinded clinical event committee 
consisting of interventional cardiologists and cardiac surgeons. In 
case of suspected cerebrovascular events, patients were assessed by a 
board-certified neurologist and underwent neurological imaging 
studies as indicated. The neurological events were adjudicated in 
consensus and guided by the expert neurological assessment accord-
ing to the endpoint definitions proposed by the Valve Academic 
Research Consortium (VARC). Baseline clinical and procedural 
characteristics as well as follow-up data were entered into a dedicated 
database, held at an academic clinical trials unit (Cardiobase, CTU 
Bern, Bern University Hospital, Switzerland) responsible for central 
data audits and maintenance of the database.
DEFINITIONS
Clinical adverse events were adjudicated according to the endpoint 
definitions proposed by VARC, described in detail elsewhere7. Cer-
ebrovascular accidents (CVA) were defined as the composite of 
major stroke, minor stroke or transient ischaemic attack (TIA). 
Stroke was defined as a rapid onset of a focal or global neurological 
deficit with change in level of consciousness, hemiplegia, hemipa-
resis, numbness or sensory loss affecting one side of the body, dys-
phasia or aphasia, hemianopia, amaurosis fugax or other 
neurological signs or symptoms consistent with stroke and con-
firmed by a neurology specialist as well as neuroimaging. The 
severity of the event was classified according to the Modified 
Rankin Scale. A stroke was considered major in the presence of 
a calculated Modified Rankin score of ≥2 and minor in the presence 
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of a calculated Modified Rankin score <2. TIA was defined as 
a new focal neurological deficit as indicated above with rapid 
symptom resolution within 24 hours in the absence of cerebral tis-
sue injury as evidenced by neuroimaging.
The number of predilations of the native valve and post-dilations 
after bioprosthesis implantation were recorded. In addition, the 
number of implantation attempts was assessed by counting the fre-
quency of valve prosthesis placement attempts prior to obtaining 
the final implantation result.
STATISTICAL ANALYSIS
Patient demographics and procedural and follow-up data were 
prospectively collected and entered in a dedicated database held 
at CTU Bern, Switzerland. All statistical analyses were performed 
by a statistician of an academic clinical trials unit (DH and PJ, 
Clinical Trials Unit Bern, Bern University Hospital, Switzerland) 
using Stata 12 (StataCorp LP, College Station, TX, USA). Con-
tinuous variables are presented as mean ± SD and are compared 
by means of unpaired t-tests. Categorical data are expressed as 
frequencies and percentages and are compared using χ2 and Fish-
er’s exact tests. Time to death was compared between the CVA 
and No CVA group using a Mantel-Cox log-rank test and pre-
sented with Kaplan-Meier curves. Endpoints up to 30 days fol-
low-up were analysed with logistic regression (crude analyses) 
and with logistic regression adjusting for the effects of body mass 
index and chronic obstructive pulmonary disease (adjusted analy-
ses). Endpoints up to 30 days follow-up with zero events in one 
group were analysed with exact logistic regression (crude 
analyses).
Results
PATIENT POPULATION
Between August 2007 and October 2011, 389 consecutive patients 
underwent TAVI for native aortic valve stenosis using the trans-
femoral, transapical or subclavian access route. During the peripro-
cedural period up to 30 days of follow-up, a total of 14 patients 
(3.6%) experienced at least one CVA, which consisted of a major 
stroke in 12 patients (3.1%) and a minor stroke in 2 patients (0.5%). 
The vast majority of CVAs occurred during or within one day of the 
procedure (Figure 1) (71.4%; major stroke, n=8; minor stroke, 
n=2). Baseline characteristics of patients with as compared to 
patients without periprocedural CVA are shown in Table 1. Patients 
suffering from CVA had a smaller body mass index (22.9%±2.6 vs. 
26.3%±5.1, p=0.01) and tended to have a higher incidence of prior 
stroke (21% vs. 7%, p=0.08) and chronic obstructive pulmonary 
disease (38% vs. 18%, p=0.08) in their past medical history as com-
pared to patients without CVA. Other risk factors for stroke includ-
ing age (81.5±6.7 vs. 82.5±5.8, p=0.51), male gender (64% vs. 
49%, p=0.26), arterial hypertension (86% vs. 78%, p=0.74), diabe-
tes mellitus (14% vs. 27%, p=0.37), smoking (21% vs. 12%, 
p=0.40) and atrial fibrillation (36% vs. 27%, p=0.54) were not dif-
ferent between the two groups. The overall surgical risk of the pre-
sent patient cohort was high as estimated by a mean EuroSCORE of 
Figure 1. Frequency distribution of cerebrovascular accidents within 
30 days after transcatheter aortic valve implantation.
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24.3±14.2% and a mean STS Score of 6.8±5.3% without apparent 
differences between patients with and without CVA during the 
periprocedural follow-up period. There were also no differences 
with respect to antithrombotic treatment at baseline between the 
two groups.
PROCEDURAL CHARACTERISTICS
Procedural characteristics are summarised in Table 2. The most fre-
quently applied implantation strategy was the retrograde, transfemoral 
access route (n=308, 79%), followed by the transapical (n=76, 20%) 
and subclavian access site (n=5, 1%). All patients underwent TAVI 
with either the Medtronic CoreValve (n=224, 58%) or the Edwards 
SAPIEN transcatheter heart valve prosthesis (n=165, 42%) with no 
differences between the two groups. The vast majority of patients 
underwent balloon dilatation of the native valve prior to valve implan-
tation (n=385, 99%) with 56 patients (14%) requiring more than one 
predilatation, whereas 4 patients (1%) were treated without balloon 
predilatation. Post-dilatation after placement of the transcatheter heart 
valve prosthesis was performed in 108 patients (28%), and implanta-
tion of more than one valve in series was required in 7 patients (2%). 
Neither the number of predilatations nor the implantation of more than 
one valve in series resulted in a higher number of CVAs. Conversely, 
more than one device implantation attempt was more commonly 
counted among patients with as compared to patients without CVA 
(29% vs. 8%, p=0.023). Similarly, there was a trend towards more 
post-dilatations among patients with than without CVA (50% vs. 27%, 
p=0.072). Although fluoroscopy time was longer in the CVA group 
(25±14 min vs. 20±10 min, p=0.05), no differences were recorded in 
terms of procedural time (89±52 min vs. 83±35 min, p=0.53), amount 
of contrast agent (287±127 ml vs. 251±95 ml, p=0.17) and treatment of 
concomitant coronary artery disease (14% vs. 16%, p=1.00). The 
antithrombotic regimen at time of discharge is shown in Table 3 with-
out significant differences in use of acetylsalicylic acid, thienopyri-
dines, dual antiplatelet therapy, and oral anticoagulation between 
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patients with and without CVA. In multivariable logistic regression 
analysis, more than one device implantation attempt (ORadjusted 8.3, CI 
2.1-33.3, p=0.003), chronic obstructive pulmonary disease (ORadjusted 
4.7, CI 1.3-16.8, p=0.02) and body mass index <25 kg/m2 (ORadjusted 
0.8, CI 0.7-0.9, p=0.01) emerged as independent predictors of peripro-
cedural CVA (Table 4).
CLINICAL OUTCOMES
Clinical outcomes through 30 days of follow-up according to 
VARC are summarised in Table 4. Overall and cardiovascular 
mortality amounted to 6.4% and 5.7%, respectively, at 30 days in 
this patient population. Patients with CVA during the periproce-
dural period had an increased risk of all-cause (42.3% vs. 5.1%, 
ORadjusted 11.7, 95% CI 3.4-40.3, p<0.001) and cardiovascular 
death (38.4% vs. 4.6%, ORadjusted 10.5, 95% CI 2.9-37.8, p<0.001) 
compared to patients without CVA in crude and adjusted analyses 
(Figure 2). There were no differences in the risk of myocardial 
infarction (0% vs. 0.5%, ORcrude 11.2, 95% CI 0.0-146.9, p=1.00), 
bleeding complications (life-threatening bleeding 7% vs. 17%, 
ORadjusted 0.4, 95% CI 0.05-3.3, p=0.40), acute renal failure (7% 
Table 1. Baseline clinical characteristics.
All patients
(n=389)
CVA
(n=14)
No CVA
(n=375)
p-value
Age (years) 82.5±5.8 81.5±6.7 82.5±5.8 0.51
Female gender, n (%) 197 (51%) 5 (36%) 192 (51%) 0.26
Body mass index (kg/m2)          26.2±5.1 22.9±2.6 26.3±5.1 0.01
Cardiac risk factors
  Diabetes mellitus, n (%) 105 (27%) 2 (14%) 103 (27%) 0.37
  Hypercholesterolaemia, n (%)       236 (61%) 9 (64%) 227 (61%) 0.79
  Hypertension, n (%) 303 (78%) 12 (86%) 291 (78%) 0.74
  Current smoker, n (%) 48 (12%) 3 (21%) 45 (12%) 0.40
Past medical history
  Previous myocardial infarction, n (%) 64 (16%) 2 (14%) 62 (17%) 1.00
  Previous coronary artery bypass graft, n (%) 72 (19%) 2 (14%) 70 (19%) 1.00
  Previous percutaneous coronary intervention, n (%) 94 (24%) 2 (14%) 92 (25%) 0.53
  Previous stroke, n (%) 30 (8%) 3 (21%) 27 (7%) 0.08
  Peripheral vascular disease, n (%) 87 (22%) 1 (7%) 86 (23%) 0.21
  Chronic obstructive pulmonary disease, n (%) 72 (19%) 5 (38%) 67 (18%) 0.08
  Atrial fibrillation, n (%) 103 (27%) 5 (36%) 98 (27%) 0.54
Clinical features
  Renal failure (GFR<60 ml/min/1.73 m2) 268 (69%) 11 (79%) 257 (69%) 0.56
  Coronary artery disease, n (%) 238 (61%) 6 (43%) 232 (62%) 0.15
  Left ventricular ejection fraction (%) 51.9±14.8 50.0±16.7 51.9±14.7 0.63
  Aortic valve area (cm2) 0.6±0.2 0.6±0.3 0.6±0.2 0.88
  Mean transaortic gradient (mmHg) 44.2±16.8 46.8±19.8 44.1±16.7 0.56
Symptoms
New York Heart Association (NYHA) Functional Class 0.88
  NYHA I, n (%) 22 (6%) 1 (7%) 21 (6%)
  NYHA II, n (%) 109 (28%) 5 (36%) 104 (28%)
  NYHA III, n (%) 206 (53%) 6 (43%) 200 (54%)
  NYHA IV, n (%) 49 (13%) 2 (14%) 47 (13%)
Risk assessment
  Logistic EuroSCORE (%) 24.3±14.2 28.7±21.7 24.1±13.8 0.23
  STS Score (%) 6.8±5.3 8.8±8.9 6.7±5.1 0.16
Antithrombotic therapy
  Aspirin, n (%) 237 (62%) 8 (62%) 229 (62%) 1.00
  Clopidogrel, n (%) 69 (18%) 1 (8%) 68 (18%) 0.48
  Oral anticoagulation, n (%) 106 (28%) 3 (23%) 103 (28%) 1.00
n   
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vs. 4%, ORadjusted 2.6, 95% CI 0.3-22.8, p=0.52) and access site 
complications (major vascular access site complications 0% vs. 
8%, ORcrude 0.6, 95% CI 0.0-3.7, p=0.64) between patients with 
and without CVA.
Table 3. Antithrombotic regimen at discharge.
All patients
(n=389)
CVA
(n=14)
No CVA
(n=375)
p-value
Aspirin, n (%) 286 (80%) 7 (88%) 279 (80%) 1.00
Clopidogrel, n (%) 257 (72%) 6 (75%) 251 (72%) 1.00
Aspirin and clopidogrel, n (%) 222 (62%) 5 (63%) 217 (62%) 1.00
Oral anticoagulation, n (%) 90 (25%) 2 (25%) 88 (25%) 1.00
Oral anticoagulation and aspirin, n (%) 40 (11%) 1 (13%) 39 (11%) 1.00
Oral anticoagulation and clopidogrel, n (%) 32 (9%) 1 (13%) 31 (9%) 0.53
Table 4. Clinical outcomes at 30 days of follow-up according to VARC.
OR (95% CI) p-value
All patients
n=389
CVA
n=14
No CVA
n=375
Crude Adjusted* Crude Adjusted*
30 days follow-up
All-cause mortality, n (%) 24 (6.4%) 6 (42.3%) 18 (5.1%) 14.9 (4.7-47.4) 11.7 (3.4-40.3) <0.001 <0.001
Cardiovascular mortality, n (%) 20 (5.7%) 5 (38.4%) 15 (4.6%) 13.3 (24.0-44.7) 10.5 (2.9-37.8) <0.001 <0.001
Myocardial infarction, n (%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 11.2 (0.0-146.9) – 1.00 –
Bleeding
Life-threatening, n (%) 64 (16%) 1 (7%) 63 (17%) 0.4 (0.05-3.0) 0.4 (0.05-3.3) 0.36 0.40
Major, n (%) 125 (32%) 6 (43%) 119 (32%) 1.6 (0.5-4.8) 1.2 (0.4-3.9) 0.39 0.73
Acute renal failure, n (%) 15 (4%) 1 (7%) 14 (4%) 2.0 (0.2-16.2) 2.6 (0.3-22.8) 0.52 0.40
Access site complications
Major, n (%) 30 (8%) 0 (0%) 30 (8%) 0.6 (0.0-3.7) – 0.64 –
Minor, n (%) 42 (11%) 2 (14%) 40 (11%) 1.4 (0.3-6.5) 2.0 (0.4-9.6) 0.67 0.40
Depicted are odds ratios (OR) from logistic regression for all-cause death, cardiovascular death, bleeding, acute renal failure and minor access site 
complications. For myocardial infarction and major vascular complications odds ratios (OR) are used from exact logistic regression analysis. *Adjusted 
for body mass index and chronic obstructive pulmonary disease.
Table 2. Procedural characteristics.
All patients
(n=389)
CVA
(n=14)
No CVA
(n=375)
p-value
Procedure time (min) 82.7±35.4 88.8±51.7 82.5±34.7 0.53
Fluoroscopy time (min) 19.8±10.3 25.1±14.3 19.6±10.1 0.049
Amount of contrast (ml) 252.2±96.7 287.0±127.0 250.9±95.3 0.17
General anaesthesia, n (%) 164 (42%) 4 (29%) 160 (43%) 0.41
New-onset atrial fibrillation, n (%) 27 (7%) 0 (0%) 27 (7%) 0.61
Access route
Femoral, n (%) 308 (79%) 12 (86%) 296 (79%) 0.74
Apical, n (%) 76 (20%) 2 (14%) 74 (20%) 1.00
Subclavian, n (%) 5 (1%) 0 (0%) 5 (1%) 1.00
Valve type 0.17
Medtronic CoreValve, n (%) 224 (58%) 11 (79%) 213 (57%)
Edwards SAPIEN valve, n (%) 165 (42%) 3 (21%) 162 (43%)
Implantation specifications
Predilation ≥2, n (%) 56 (14%) 4 (29%) 52 (14%) 0.13
Post-dilation ≥1, n (%) 108 (28%) 7 (50%) 101 (27%) 0.072
Implantation attempts >1, n 
(%) 33 (9%) 4 (29%) 29 (8%) 0.023
Valve in series, n (%) 7 (2%) 1 (7%) 6 (2%) 0.23
Revascularisation
Concomitant PCI, n (%) 63 (16%) 2 (14%) 6 (16%) 1.00
Staged PCI, n (%) 35 (9%) 0 (0%) 35 (9%) 0.63
Figure 2. Cumulative incidence of all-cause mortality among 
patients with and without cerebrovascular accidents within 30 days 
after transcatheter aortic valve implantation. Patients without 
cerebrovascular event (blue line, no CVA) and patients with 
cerebrovascular events (red line, CVA).
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Discussion
The present study reporting on the frequency, timing and impact of 
periprocedural CVA among patients undergoing TAVI has the fol-
lowing main findings:
–  The incidence of CVA after TAVI was low in this elderly, high-
risk patient population with the vast majority of events occurring 
during the immediate periprocedural period.
–  Independent predictors of periprocedural CVA comprised the 
Table 5. Characteristics of patients with cerebrovascular events.
Patient
Patient in 
series
Age
Access 
route
Time after 
TAVI
Type of CVA 
(VARC)
Symptoms Classification
#1 #47 91 TF 14d Major stroke Left facial palsy and left side accentuated arm 
paresis
Uncertain
#2 #49 83 TF 23d Major stroke Left-sided hemiparesis Uncertain
#3 #105 90 TF 1d Major stroke Left-sided hemiparesis Lacunar type (new multifocal spots)
#4 #114 77 TA 1d Major stroke Left side accentuated arm paresis Lacunar type (old multifocal spots)
#5 #133 76 TF 1d Major stroke Leg accentuated lack of strength Lacunar type (new multifocal spots)
#6 #172 81 TF 0d Major stroke Right facial palsy, arm paresis and stupor Uncertain
#7 #181 64 TA 4d Major stroke Left side accentuated neglect Cortical type (new multifocal spots)
#8 #192 86 TF 1d Major stroke Left-sided hemiparesis Lacunar type (new multifocal spots)
#9 #214 77 TF 0d Major stroke Left-sided hemiparesis Lacunar type (old multifocal spots)
#10 #220 86 TF 13d Major stroke Right arm paresis Cortical type (old single spots)
#11 #264 84 TF 0d Major stroke Apraxia Lacunar type (new multifocal spots)
#12 #321 78 TF 0d Minor stroke Left-sided hemiparesis, hemianopia and neglect Lacunar type (neuroradiological intervention with 
extraction of thrombus material and local 
thrombolysis resulting in full neurological recovery)
#13 #368 82 TF 0d Minor stroke Diplopia Uncertain
#14 #369 85 TF 0d Major stroke Left-sided hemiparesis Lacunar type (new multifocal spots)
Figure 3. Crude and adjusted odds ratios of the endpoint cerebrovascular accidents within 30 days of transcatheter aortic valve implantation 
stratified across subgroups.
OR (95% CI) p-value
CVA events/n Crude CrudeAdjusted* Adjusted*
Odds ratio (95% CI)
 .2 .5 1 2 4 8 16
Body mass index group
≥25 kg/m2 4/212 0.32 (0.10-1.04) 0.78 (0.66-0.92) 0.06 0.01
<25 kg/m2 10/177
Chronic obstructive pulmonary disease
Yes 5/72 2.85 (0.90-8.97) 4.73 (1.33-16.79) 0.07 0.02
No 8/133
Implantation attempts >1
Two or more  4/33 4.77 (1.41-16.16) 8.32 (2.08-33.26) 0.01 0.003
One 10/356
Previous stroke
Yes 3/30 3.52 (0.92-13.36) 1.87 (0.33-10.62)
No 11/359
Post-dilation ≥1
One or more 7/108 2.69 (0.92-7.87) 2.00 (0.62-6.49) 0.07 0.25
Zero 7/279
 lower risk of CVA higher risk of CVA
*Adjusted for body mass index, chronic obstructive pulmonary disease and implantation attempts >1; Body mass index events per group shown for illustrative 
purposes above and below the mean of 25 kg/m2; Crude: white symbols; Adjusted: black symbols
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number of device implantation attempts, chronic obstructive pul-
monary disease and body mass index below 25 kg/m2.
–  A CVA was associated with a 10-fold increased risk of overall and 
cardiovascular mortality within 30 days.
The incidence of CVA in this elderly, high-risk patient population 
undergoing TAVI amounted to 3.6% at 30 days. This rate is consist-
ent with previously published reports of large-scale registries8 and 
has to be interpreted in the context of the risk profile of octogenar-
ians with a high prevalence of cardiovascular risk factors, coronary 
and peripheral vascular disease, and atrial fibrillation. It is also 
comparable to rates of CVA as reported in the randomised Place-
ment of Transcatheter Aortic Valves (PARTNER A and B) trial. 
Compared with medical treatment, TAVI was associated with 
a somewhat higher risk of major stroke at 30 days in PARTNER B 
(5.0% versus 1.1%, p=0.06), whereas there were no differences 
between TAVI and SAVR during the periprocedural period in 
PARTNER A (3.8% versus 2.1%, p=0.20).
CVA during the periprocedural period of TAVI may be related to 
specific patient and procedural characteristics. Classical risk factors for 
stroke like age, gender, arterial hypertension, atrial fibrillation or diabe-
tes mellitus9 were not predictive for a CVA but patients with CVA more 
often had a low body mass index, chronic obstructive pulmonary dis-
ease and experienced a stroke in their past medical history.
Several studies have reported a higher incidence of stroke 
among patients with new onset atrial fibrillation after TAVI. 
Along this line, Amat-Santos et al have observed an incidence of 
new-onset atrial fibrillation of 32% among patients undergoing 
TAVI, which was associated with an increased risk of stroke and 
systemic embolism. In contrast, new-onset atrial fibrillation was 
observed only in 7% of patients in the present study population, 
predominantly undergoing TAVI via the transfemoral access 
route. The rate of new onset of atrial fibrillation in the present 
study is well in line with the 8.6% incidence observed in the 
PARTNER cohort A study, and it did not emerge as an independ-
ent predictor of stroke. Nevertheless, new-onset atrial fibrillation 
is known to affect clinical outcome adversely following surgical 
aortic valve replacement10,11, and therefore preventive strategies 
and optimal anticoagulation regimens among affected patients 
remain to be determined.
The majority of CVAs accumulate in the early periprocedural 
period1,2,5. Thromboembolic events with cerebrovascular injury may 
occur at various stages during TAVI: 1) retrograde passage of the cal-
cified aortic valve12,13; 2) predilatation of the native valve; 3) advance-
ment of the delivery catheter through the aortic arch and deployment 
of the prosthesis14. Previous studies reported on the detection of new 
intracranial lesions distributed in both hemispheres using diffusion-
weighted magnetic resonance neuroimaging suggesting a high preva-
lence of cerebral thromboembolism during TAVI15-18. The concept of 
cerebral embolism is further supported by transcranial Doppler ultra-
sonography studies recording a high number of high-intensity tran-
sient signals (HITS) during the various stages of TAVI14,19. Although 
the majority of intracranial lesions identified by magnetic resonance 
imaging remained clinically silent, an adverse effect of cerebral 
embolism resulting in behavioural or cognitive impairment has not 
been sufficiently investigated to date.
To the best of our knowledge, this study is the first report on the 
association of procedural steps of TAVI and the risk of stroke. The 
number of device implantation attempts emerged as an independ-
ent predictor of stroke and was associated with an eight-fold 
increased risk of periprocedural CVA in the present study. This 
observation suggests that any additional manipulation in the aor-
tic arch, the ascending aorta or the native aortic valve may con-
tribute to an increased risk of periprocedural stroke but also point 
to the potential of preventive strategies during the periprocedural 
period. Embolic protection devices, recently introduced in clinical 
practice, either deviate or filter thromboembolic debris during the 
intervention. Three dedicated devices for the reduction of CVA 
have been tested in human: the Embrella embolic protection 
device (Edwards Lifesciences, Irvine, CA, USA)20 delivered 
through the right radial artery has a specific heparin-coated polyu-
rethane membrane which is designed to cover the ostia of the bra-
chiocephalic trunk and the left common carotid artery, thereby 
deflecting embolic debris from the cerebral circulation. The SMT 
Shimon Embolic protection filter (SMT Medical, Herzliya 
Pituach, Israel) is another embolic deflection device, introduced 
femorally. The Claret CE Pro™ (Claret Medical, Inc., Santa Rosa, 
CA, USA)21 is designed to capture debris in two filters placed in 
the brachiocephalic trunk and the left common carotid artery. It 
provides the possibility of retrieving debris and not only deflect-
ing the embolic material. Recent studies demonstrated the feasi-
bility of these devices and the ease of use. Clinical trials proving 
a benefit with respect to reducing the CVA event rate are however 
missing. Therefore, the routine use of cerebral protection devices 
cannot be recommended so far and requires careful scrutiny. 
Another focus of CVA prevention is an improvement of antithrom-
botic and antiplatelet regimens. An optimal antiplatelet therapy 
carries the potential to reduce not only the periprocedural risk but 
also the long-term risk of a CVA in this high-risk patient popula-
tion. Following surgical aortic valve replacement using a biopros-
thesis, a low dose acetylsalicylic acid (100 mg) regimen is 
recommended whereas dual antiplatelet therapy with acetylsali-
cylic acid in combination with clopidogrel (75 mg per day) for six 
months represents the favoured strategy after TAVI. Oral antico-
agulation with the use of vitamin K antagonists or direct thrombin 
inhibitors in addition to low dose aspirin are considered as the 
most favourable treatment options in patients with atrial fibrilla-
tion. Further studies are required to determine the optimal medical 
treatment strategy in this elderly patient population with a high 
risk of stroke undergoing TAVI.
Similar to previous reports, patients suffering from periproce-
dural CVA had impaired clinical outcome in terms of all-cause and 
cardiovascular mortality in our study. Of note, the risk of death was 
increased more than 10-fold in an adjusted analysis highlighting the 
deleterious effect of a cerebrovascular event on clinical outcome. 
Moreover, CVA abolishes the improvement of symptoms and other 
quality of life measures usually observed after TAVI.
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The current study has some limitations that might influence the 
significance and the strength of the results. First, the study popula-
tion is based on the experience of a single, tertiary care centre. This 
limits the generalisability of the findings and may not apply to other 
centres using a different mixture of devices and procedural and 
post-procedural anticoagulation regimens. Second, the low rate of 
cerebrovascular events has to be considered when interpreting the 
results of the present study and may result in over-fitting in the 
regression model. However, we report both crude and adjusted 
analyses of all outcome variables and found results to be robust, 
supporting the conclusions of this study. Third, prior to the advent 
of the VARC criteria, cerebrovascular accidents were recorded 
according to the clinical neurological examination and cerebral 
imaging results, as performed by a board-certified neurologist and 
adjudicated by the interdisciplinary clinical event committee. By 
January 2011, all endpoints including cerebrovascular accidents 
were re-adjudicated according to the clinical endpoint definitions 
proposed by VARC and since then the Modified Rankin Scale was 
prospectively recorded and used for assessment of stroke severity. 
Finally, we did not record the time required to cross the aortic valve 
retrogradely or the extent of calcification of the aortic valve, the 
ascending aorta and the aortic arch, which may have an important 
impact on the periprocedural risk of stroke.
Conclusion
Cerebrovascular accidents in TAVI patients occur predominantly 
during the periprocedural period, are independently predicted by 
multiple implantation attempts of the bioprosthesis and signifi-
cantly impair clinical outcome as reflected by an increased mortal-
ity rate.
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